Dear Democracy Now! Visitor: We are an independent, ad-free daily news program that serves millions of viewers and listeners each month. Our show is special because we make it our priority to go where the silence is. We put a spotlight on corporate and government abuses of power and lift up the stories of ordinary people working to make change in extraordinary times. We do all of this with just a fraction of the budget and staff of a commercial news show. We do it without ads, corporate sponsorship or government funding. How is this possible? Only with your support. If everyone who visited our website in the next week donated just $15, we would cover all of our operating costs for the year. We can't do it without you. Please donate today. It takes just a couple of minutes to do your part to make sure Democracy Now! is there for you and everybody else.

Your Donation: $

India Supreme Court Rejects Swiss Drug Giant’s Effort to Block Generic Drugs

India’s Supreme Court has issued a landmark ruling rejecting a longtime effort by the Swiss pharmaceutical giant Novartis to block production of cheaper generic drugs. Novartis has sought patent protection for the cancer drug Glivec in India since 2006. The case was seen as a critical test of India’s ability to manufacture low-cost generic drugs that are distributed throughout the global South to treat infectious diseases. Speaking outside the courtroom earlier today, Leena Menghaney of the medical charity Doctors Without Borders praised the court’s decision.

Leena Menghaney: "It’s a huge relief, because we have more than 200,000 people living with HIV on treatment. Eighty percent of them come from India, the drugs come from India, so we were really worried that a Novartis win would mean that less number of drugs would be available for MSF procurement. So it’s a big, big relief for us that the drugs are now safe and secure and available to patients in developing countries."

On the eve of the ruling, Novartis had threatened to stop sending new medicines to India if the court did not decide in its favor. The judgment will likely affect other major pharmaceutical companies and their drug brands in India.

See all headlines for this show

Creative Commons License The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.